Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Formulation and Development of Hyaluronic Acid based Gel with Ketoconazole-Loaded Nanostructured Lipid Carriers in Fungal Infection

Author(s): Sadhana Raut*, Nupur Gargate, Sharddha Ugale, Kishor N. Gujar and Harshad Kapare

Volume 11, Issue 4, 2023

Published on: 19 April, 2023

Page: [344 - 354] Pages: 11

DOI: 10.2174/2211738511666230310103017

Price: $65

Abstract

Background: Ketoconazole is an imidazole ring containing antifungal agent used in the treatment of systemic fungal infections. It acts by blocking the synthesis of ergosterol, an essential component of the fungal cell membrane.

Objective: The purpose of this work is to construct skin targeting ketoconazole nanostructured lipid carriers (NLCs) loaded hyaluronic acid (HA) modified gel to minimize side effects and provide a controlled release.

Methods: The NLCs were prepared using emulsion sonication method and their optimized batches were characterized for X-ray diffraction, scanning electron microscopy and fourier transform infrared spectroscopy study. These batches were then incorporated into HA containing gel for convenient application. The final formulation was compared with the marketed formulation for studying its antifungal activity and drug diffusion.

Results: Ketoconazole NLCs loaded hyaluronic acid formulation was successfully developed with desirable formulation parameters by using 23 Factorial design. In vitro release study of developed formulation showed prolonged drug release (up to 5 hrs) while ex vivo drug diffusion study on human cadaver skin showed better drug diffusion as compared with marketed formulation. Moreover, the release study and diffusion study results reflected the improvement of antifungal activity of the developed formulation against Candida albicans.

Conclusion: The work suggests that ketoconazole NLCs loaded HA modified gel provides prolonged release. The formulation also has good drug diffusion and antifungal activity and thus can act as a promising carrier for topical delivery of ketoconazole.

« Previous Next »
Graphical Abstract

[1]
Centres for Disease Control and Prevention. Candidiasis. Available from: https://www.cdc.gov/fungal/diseases/candidiasis/index.html
[2]
Tripathi KD. Essential of Medical Pharmacology. (6th ed.), India Jaypee Digital 2008.
[http://dx.doi.org/10.5005/jp/books/10282]
[3]
Wen H, Jung H, Li X. Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges. AAPS J 2015; 17(6): 1327-40.
[http://dx.doi.org/10.1208/s12248-015-9814-9] [PMID: 26276218]
[4]
Korting HC, Schäfer-Korting M. Carriers in the topical treatment of skin disease. Handb Exp Pharmacol 2010; 197(197): 435-68.
[http://dx.doi.org/10.1007/978-3-642-00477-3_15] [PMID: 20217539]
[5]
Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. J Pharm Investig 2013; 43(5): 353-62.
[http://dx.doi.org/10.1007/s40005-013-0087-y]
[6]
Saini R, Saini S, Sharma S. Nanotechnology: The future medicine. J Cutan Aesthet Surg 2010; 3(1): 32-3.
[http://dx.doi.org/10.4103/0974-2077.63301] [PMID: 20606992]
[7]
Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 2013; 7(1): 41-55.
[http://dx.doi.org/10.2174/187221013804484827] [PMID: 22946628]
[8]
Ardizzoni A, Neglia RG, Baschieri MC, et al. Influence of hyaluronic acid on bacterial and fungal species, including clinically relevant opportunistic pathogens. J Mater Sci Mater Med 2011; 22(10): 2329-38.
[http://dx.doi.org/10.1007/s10856-011-4408-2] [PMID: 21892787]
[9]
Trombino S, Servidio C, Curcio F, Cassano R. Strategies for hyaluronic acid-based hydrogel design in drug delivery. Pharmaceutics 2019; 11(8): 407.
[http://dx.doi.org/10.3390/pharmaceutics11080407] [PMID: 31408954]
[10]
Shah R, Eldridge D, Palombo E, Harding I. Lipid nanoparticles: Production, characterization and stability. (1st ed.), New York, NY, USA: Springer International Publishing 2015.
[11]
Schwarz JC, Weixelbaum A, Pagitsch E, Löw M, Resch GP, Valenta C. Nanocarriers for dermal drug delivery: Influence of preparation method, carrier type and rheological properties. Int J Pharm 2012; 437(1-2): 83-8.
[http://dx.doi.org/10.1016/j.ijpharm.2012.08.003] [PMID: 22903049]
[12]
Mehnert W, Mäder K. Solid lipid nanoparticles. Adv Drug Deliv Rev 2012; 64: 83-101.
[http://dx.doi.org/10.1016/j.addr.2012.09.021] [PMID: 11311991]
[13]
Yu Q, Hu X, Ma Y, et al. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus. Drug Deliv 2016; 23(4): 1469-75.
[http://dx.doi.org/10.3109/10717544.2016.1153744] [PMID: 27187522]
[14]
Mu Y, Li J, Kang JH, et al. A Lipid-Based Nanocarrier Containing Active Vitamin D3 Ameliorates NASH in Mice via Direct and Intestine-Mediated Effects on Liver Inflammation. Biol Pharm Bull 2020; 43(9): 1413-20.
[http://dx.doi.org/10.1248/bpb.b20-00432] [PMID: 32879216]
[15]
Patil GB, Patil ND, Deshmukh PK, Patil PO, Bari SB. Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach. Artif Cells Nanomed Biotechnol 2016; 44(1): 12-9.
[http://dx.doi.org/10.3109/21691401.2014.909820] [PMID: 24866725]
[16]
Zhou X, Zhang X, Ye Y, et al. Nanostructured lipid carriers used for oral delivery of oridonin: An effect of ligand modification on absorption. Int J Pharm 2015; 479(2): 391-8.
[http://dx.doi.org/10.1016/j.ijpharm.2014.12.068] [PMID: 25556104]
[17]
Ranpise NS, Korabu SS, Ghodake VN. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces 2014; 116: 81-7.
[http://dx.doi.org/10.1016/j.colsurfb.2013.12.012] [PMID: 24445002]
[18]
Abbasalipo R, Salehzadeh A, Abdullah R. Characterization and stability of nanostructured lipid carriers as drug delivery system. Pak J Biol Sci 2012; 15(3): 141-6.
[http://dx.doi.org/10.3923/pjbs.2012.141.146] [PMID: 22866544]
[19]
Bohrey S, Chourasiya V, Pandey A. Polymeric nanoparticles containing diazepam: preparation, optimization, characterization, in vitro drug release and release kinetic study. Nano Converg 2016; 3(1): 3.
[http://dx.doi.org/10.1186/s40580-016-0061-2] [PMID: 28191413]
[20]
Puglia C, Blasi P, Rizza L, et al. Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. Int J Pharm 2008; 357(1-2): 295-304.
[http://dx.doi.org/10.1016/j.ijpharm.2008.01.045] [PMID: 18343059]
[21]
Tichota DM, Silva AC, Sousa Lobo JM, Amaral MH. Design, characterization, and clinical evaluation of argan oil nanostructured lipid carriers to improve skin hydration. Int J Nanomedicine 2014; 9: 3855-64.
[PMID: 25143733]
[22]
Zhang WL, Gu X, Bai H, Yang RH, Dong CD, Liu JP. Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. Int J Pharm 2010; 391(1-2): 313-21.
[http://dx.doi.org/10.1016/j.ijpharm.2010.03.011] [PMID: 20214958]
[23]
Okonogi S, Riangjanapatee P. Physicochemical characterization of lycopene-loaded nanostructured lipid carrier formulations for topical administration. Int J Pharm 2015; 478(2): 726-35.
[http://dx.doi.org/10.1016/j.ijpharm.2014.12.002] [PMID: 25479097]
[24]
Patel D, Dasgupta S, Dey S, Ramani YR, Ray S, Mazumder B. Nanostructured Lipid Carriers (NLC)-Based Gel for Topical Delivery of Aceclofenac: Preparation, Characterization and In vivo Evaluation. Sci Pharm 2012; 80(3): 749-64.
[http://dx.doi.org/10.3797/scipharm.1202-12] [PMID: 23008819]
[25]
Trombino S, Servidio C, Curcio F, Cassano R. Strategies or hyaluronic acid-based hydrogel design in drug delivery. Pharmaceutics 2019; 11(8): 407.
[http://dx.doi.org/10.3390/pharmaceutics11080407] [PMID: 31408954]
[26]
Kesharwani P, Jain A, Srivastava AK, Keshari MK. Systematic development and characterization of curcumin-loaded nanogel for topical application. Drug Dev Ind Pharm 2020; 46(9): 1443-57.
[http://dx.doi.org/10.1080/03639045.2020.1793998] [PMID: 32644836]
[27]
Han F, Yin R, Che X, et al. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: Design, characterization and in vivo evaluation. Int J Pharm 2012; 439(1-2): 349-57.
[http://dx.doi.org/10.1016/j.ijpharm.2012.08.040] [PMID: 22989987]
[28]
Khurana S, Jain NK, Bedi PMS. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam. Life Sci 2013; 93(21): 763-72.
[http://dx.doi.org/10.1016/j.lfs.2013.09.027] [PMID: 24113071]
[29]
Uprit S, Kumar Sahu R, Roy A, Pare A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J 2013; 21(4): 379-85.
[http://dx.doi.org/10.1016/j.jsps.2012.11.005] [PMID: 24227958]
[30]
Rao Y, Zheng F, Liang X, Wang H, Zhang J, Lu X. Penetration profile and human cadaver skin distribution of finasteride from vesicular nanocarriers. Drug Deliv 2015; 22(8): 1003-9.
[http://dx.doi.org/10.3109/10717544.2013.839128] [PMID: 24093547]
[31]
Tung NT, Huyen VT, Chi SC. Topical delivery of dexamethasone acetate from hydrogel containing nanostructured liquid carriers and the drug. Arch Pharm Res 2015; 38(11): 1999-2007.
[http://dx.doi.org/10.1007/s12272-015-0608-5] [PMID: 25940221]
[32]
Ridolfi DM, Marcato PD, Justo GZ, Cordi L, Machado D, Durán N. Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Colloids Surf B Biointerfaces 2012; 93: 36-40.
[http://dx.doi.org/10.1016/j.colsurfb.2011.11.051] [PMID: 22244299]
[33]
Bikkad ML, Nathani AH, Mandlik SK, Shrotriya SN, Ranpise NS. Halobetasol propionate-loaded solid lipid nanoparticles (SLN) for skin targeting by topical delivery. J Liposome Res 2014; 24(2): 113-23.
[http://dx.doi.org/10.3109/08982104.2013.843192] [PMID: 24131382]
[34]
Boatto HF, Girao M, Francisco EC, Machado A, de Moraes M, Fischman O. Susceptibility to Fluconazole and Ketoconazole of Candida spp. Isolated from Primary and Episodic Vulvovaginites by E-Test. Open J Obstet Gynecol 2016; 6(12): 689-97.
[http://dx.doi.org/10.4236/ojog.2016.612086]
[35]
Isham N, Ghannoum MA. Antifungal activity of miconazole against recent Candida strains. Mycoses 2010; 53(5): 434-7.
[http://dx.doi.org/10.1111/j.1439-0507.2009.01728.x] [PMID: 19531099]
[36]
Singh J, Singh J, Zaman M, Gupta AK. Evaluation of microdilution and disk diffusion methods for antifungal susceptibility testing of dermatophytes. Med Mycol 2007; 45(7): 595-602.
[http://dx.doi.org/10.1080/13693780701549364] [PMID: 17885958]
[37]
S P, T R, Dandagi PM. Formulation and evaluation of proniosome based drug delivery system of the antifungal drug clotrimazole. International Journal of Pharmaceutical Sciences and Nanotechnology 2013; 6(1): 1945-51.
[http://dx.doi.org/10.37285/ijpsn.2013.6.1.4]
[38]
Pardeike J, Weber S, Haber T, et al. Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm 2011; 419(1-2): 329-38.
[http://dx.doi.org/10.1016/j.ijpharm.2011.07.040] [PMID: 21839157]
[39]
Bhatia M, Srivastav M, Devi S, Sharma SK, Kakkar V, Saini K. Optimization and evaluation of ketoconazole loaded nanostructured lipid carriers employing microwave assisted technique. Int J Pharm Sci 2022; pp. 162-72.
[40]
Shahid M, Hussain A, Khan AA, et al. Ketoconazole-Loaded Cationic Nanoemulsion: In vitro – Ex Vivo – In vivo Evaluations to Control Cutaneous Fungal Infections. ACS Omega 2022; 7(23): 20267-79.
[http://dx.doi.org/10.1021/acsomega.2c02219] [PMID: 35721949]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy